Publisher
Springer Nature Singapore
Reference83 articles.
1. Abbasi A, Movahedpour A, Amiri A, Najaf MS, Mostafavi-Pour Z (2021) Darolutamide as a second-generation androgen receptor inhibitor in the treatment of prostate cancer. Curr Mol Med 21(4):332–346
2. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14:130–146
3. Bemis TA, La Clair JJ, Burkart MD (2021) Unraveling the role of linker design in proteolysis targeting chimeras: miniperspective. J Med Chem 64(12):8042–8052
4. Bernassola F, Karin M, Ciechanover A, Melino G (2008) The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14(1):10–21
5. Buckley DL, Raina K, Darricarrere N, Hines J, Gustafson JL, Smith IE, Miah AH, Harling JD, Crews CM (2015) HaloPROTACS: use of small molecule PROTACs to induce degradation of HaloTag fusion proteins. ACS Chem Biol 10:1831–1837